Application of biorelevant dissolution tests to the prediction of in vivo performance of diclofenac sodium from an oral modified-release pellet dosage form

European Journal of Pharmaceutical Sciences

Volumn 37, Issue 3-4, 2009, Pages 434-441

  Jantratid, Ekarat ^a   De Maio, Vincenzo ^b   Ronda, Emanuela ^b   Mattavelli, Valentina ^b   Vertzoni, Maria ^c   Dressman, Jennifer B ^a  

^a GOETHE UNIVERSITY   (Germany)

^b Eurand International SpA   (Italy)

^c UNIVERSITY OF ATHENS   (Greece)

Author keywords

Bio Dis; Biorelevant dissolution tests; Diclofenac sodium; Flow through cell; Food effects; In vitro in vivo correlations

Indexed keywords

DICLOFENAC;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSSOVER PROCEDURE; DISSOLUTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG PELLET; EXPERIMENTAL DESIGN; FEMALE; FOOD; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; INTERMETHOD COMPARISON; MALE; NORMAL HUMAN; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIMULATION; SLOW DRUG RELEASE;

ADMINISTRATION, ORAL; ADULT; ALGORITHMS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DICLOFENAC; FEMALE; FORECASTING; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; QUALITY CONTROL; SOLUBILITY; YOUNG ADULT;

EID: 67349187909     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2009.03.015     Document Type: Article

References (46)

1. Abrahamsson B., Johansson D., Torstensson A., and Wingstrand K. Evaluation of solubilizers in the drug release testing of hydrophilic matrix extended-release tablets of felodipine. Pharm. Res. 11 (1994) 1093-1097
2. Amidon G.L., Lennernäs H., Shah V.P., and Crison J.R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12 (1995) 413-420
3. Balan G., Timmins P., Greene D.S., and Marathe P.H. In vitro-in vivo correlation (IVIVC) models for metformin after administration of modified-release (MR) oral dosage forms to healthy human volunteers. J. Pharm. Sci. 90 (2001) 1176-1185
4. Chuasuwan B., Binjesoh V., Polli J.E., Zhang H., Amidon G.L., Junginger H.E., Midha K.K., Shah V.P., Stavchansky S., Dressman J.B., and Barends D.M. Biowaiver monographs for immediate release solid oral dosage forms: diclofenac sodium and diclofenac potassium. J. Pharm. Sci. 98 (2009) 1206-1219
5. Clarysse S., Tack J., Lammert F., Duchateau G., Reppas C., and Augustijns P. Postprandial evolution in composition and characteristics of human duodenal fluids in different nutritional states. J. Pharm. Sci. 98 (2009) 1177-1192
6. Coupe A.J., Davis S.S., and Wilding I.R. Variation in gastrointestinal transit of pharmaceutical dosage forms in healthy subjects. Pharm. Res. 8 (1991) 360-364
7. Davis S.S., Hardy J.G., and Fara J.W. Transit of pharmaceutical dosage forms through the small intestine. Gut 27 (1986) 886-892
8. Dressman J., Schamp K., Beltz K., and Alsenz J. Characterizing release from lipid-based formulations. In: Hauss D.J. (Ed). Oral Lipid-Based Formulations: Enhancing the Bioavailability of Poorly Water-Soluble Drugs (2007), Informa Healthcare USA, Inc., New York 241-256
9. Dressman J.B., Amidon G.L., Reppas C., and Shah V.P. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm. Res. 15 (1998) 11-22
10. Dressman J.B., Berardi R.R., Dermentzoglou L.C., Russell T.L., Schmaltz S.P., Barnett J.L., and Jarvenpaa K.M. Upper gastrointestinal (GI) pH in young, healthy men and women. Pharm. Res. 7 (1990) 756-761
11. Dressman J.B., and Reppas C. In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs. Eur. J. Pharm. Sci. 11 Suppl. 2 (2000) S73-S80
12. Emami J. In vitro-in vivo correlation: from theory to applications. J. Pharm. Pharm. Sci. 9 (2006) 169-189
13. Fotaki N., Symillides M., and Reppas C. In vitro versus canine data for predicting input profiles of isosorbide-5-mononitrate from oral extended release products on a confidence interval basis. Eur. J. Pharm. Sci. 24 (2005) 115-122
14. Frick A., Moller H., and Wirbitzki E. Biopharmaceutical characterization of oral controlled/modified-release drug products. In vitro/in vivo correlation of roxatidine. Eur. J. Pharm. Biopharm. 46 (1998) 313-319
15. Galia E., Nicolaides E., Hörter D., Löbenberg R., Reppas C., and Dressman J.B. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm. Res. 15 (1998) 698-705
16. Hardy J.G., Harvey W.J., Sparrow R.A., Marshall G.B., Steed K.P., Macarios M., and Wilding I.R. Localization of drug release sites from an oral sustained-release formulation of 5-ASA (Pentasa) in the gastrointestinal tract using gamma scintigraphy. J. Clin. Pharmacol. 33 (1993) 712-718
17. Jantratid E., Janssen N., Chokshi H., Tang K., and Dressman J.B. Designing biorelevant dissolution tests for lipid formulations: case example-lipid suspension of RZ-50. Eur. J. Pharm. Biopharm. 69 (2008) 776-785
18. Jantratid E., Janssen N., Reppas C., and Dressman J.B. Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update. Pharm. Res. 25 (2008) 1663-1676
19. Kalantzi L., Goumas K., Kalioras V., Abrahamsson B., Dressman J.B., and Reppas C. Characterization of the human upper gastrointestinal contents under conditions simulating bioavailability/bioequivalence studies. Pharm. Res. 23 (2006) 165-176
20. Klein, S., 2005. Biorelevant dissolution test methods for modified release dosage forms. Doctoral thesis. Department of Pharmaceutical Technology, Goethe University, Frankfurt am Main, 312 pp.
21. Klein S., Rudolph M.W., Skalsky B., Petereit H.U., and Dressman J.B. Use of the BioDis to generate a physiologically relevant IVIVC. J. Control. Release 130 (2008) 216-219
22. Klein S., Wunderlich M., and Dressman J. Development of dissolution tests on the basis of gastrointestinal physiology. In: Dressman J., and Krämer J. (Eds). Pharmaceutical Dissolution Testing (2005), Taylor & Francis Group, LLC, Boca Raton, FL
23. Kortejärvi H., Mikkola J., Bäckman M., Antila S., and Marvola M. Development of level A, B and C in vitro-in vivo correlations for modified-release levosimendan capsules. Int. J. Pharm. 241 (2002) 87-95
24. Langenbucher F. Interpretation of in vitro-in vivo time profiles in terms of extent, rate, and shape. In: Dressman J., and Krämer J. (Eds). Pharmaceutical Dissolution Testing (2005), Taylor & Francis, Florida 251-279
25. Levy G., and Hollister L.E. Inter- and intrasubject variations in drug absorption kinetics. J. Pharm. Sci. 53 (1964) 1446-1452
26. Levy G., Leonards J.R., and Procknal J.A. Development of in vitro dissolution tests which correlate quantitatively with dissolution rate-limited drug absorption in man. J. Pharm. Sci. 51 (1965) 1719-1722
27. Lue B.M., Nielsen F.S., Magnussen T., Schou H.M., Kristensen K., Jacobsen L.O., and Mullertz A. Using biorelevant dissolution to obtain IVIVC of solid dosage forms containing a poorly-soluble model compound. Eur. J. Pharm. Biopharm. 69 (2008) 648-657
28. Nicolaides E., Galia E., Efthymiopoulos C., Dressman J.B., and Reppas C. Forecasting the in vivo performance of four low solubility drugs from their in vitro dissolution data. Pharm. Res. 16 (1999) 1876-1882
29. Nicolaides E., Symillides M., Dressman J.B., and Reppas C. Biorelevant dissolution testing to predict the plasma profile of lipophilic drugs after oral administration. Pharm. Res. 18 (2001) 380-388
30. O'Connor K.M., and Corrigan O.I. Preparation and characterisation of a range of diclofenac salts. Int. J. Pharm. 226 (2001) 163-179
31. Riad L.E., Sawchuk R.J., McAlary M.M., and Chan K.K. Effect of food on the multiple-peak behavior after a single oral dose of diclofenac sodium slow-release tablet in humans. Am. J. Ther. 2 (1995) 237-242
32. Rossi R.C., Dias C.L., Donato E.M., Martins L.A., Bergold A.M., and Fröehlich P.E. Development and validation of dissolution test for ritonavir soft gelatin capsules based on in vivo data. Int. J. Pharm. 338 (2007) 119-124
33. Russell T.L., Berardi R.R., Barnett J.L., Dermentzoglou L.C., Jarvenpaa K.M., Schmaltz S.P., and Dressman J.B. Upper gastrointestinal pH in seventy-nine healthy, elderly, North American men and women. Pharm. Res. 10 (1993) 187-196
34. Sunesen V.H., Pedersen B.L., Kristensen H.G., and Müllertz A. In vivo in vitro correlations for a poorly soluble drug, danazol, using the flow-through dissolution method with biorelevant dissolution media. Eur. J. Pharm. Sci. 24 (2005) 305-313
35. Takka S., Sakr A., and Goldberg A. Development and validation of an in vitro-in vivo correlation for buspirone hydrochloride extended release tablets. J. Control. Release 88 (2003) 147-157
36. Uppoor V.R. Regulatory perspectives on in vitro (dissolution)/in vivo (bioavailability) correlations. J. Control. Release 72 (2001) 127-132
37. US FDA, 1997a. Guidance for Industry: Dissolution testing of immediate-release solid oral dosage forms. Food and Drug Administration, Center for Drug Evaluation and Research (CDER).
38. US FDA, 1997b. Guidance for Industry: Extended release oral dosage forms: Development, evaluation, and application of in vitro/in vivo correlations. Food and Drug Administration, Center for Drug Evaluation and Research (CDER).
39. US FDA, 2002. Guidance for Industry: Food-effect bioavailability and fed bioequivalence studies. Food and Drug Administration, Center for Drug Evaluation and Research (CDER).
40. USP 30, 2008. United States Pharmacopeial Convention, Inc., Rockville, MD.
41. Vertzoni M., Dressman J., Butler J., Hempenstall J., and Reppas C. Simulation of fasting gastric conditions and its importance for the in vivo dissolution of lipophilic compounds. Eur. J. Pharm. Biopharm. 60 (2005) 413-417
42. Vertzoni M., Fotaki N., Kostewicz E., Stippler E., Leuner C., Nicolaides E., Dressman J., and Reppas C. Dissolution media simulating the intralumenal composition of the small intestine: physiological issues and practical aspects. J. Pharm. Pharmacol. 56 (2004) 453-462
43. Wei H., and Löbenberg R. Biorelevant dissolution media as a predictive tool for glyburide a class II drug. Eur. J. Pharm. Sci. 29 (2006) 45-52
44. Willis J.V., Kendall M.J., Flinn R.M., Thornhill D.P., and Welling P.G. The pharmacokinetics of diclofenac sodium following intravenous and oral administration. Eur. J. Clin. Pharmacol. 16 (1979) 405-410
45. Willis J.V., Kendall M.J., and Jack D.B. The influence of food on the absorption of diclofenac after single and multiple oral doses. Eur. J. Clin. Pharmacol. 19 (1981) 33-37
46. Wingstrand K., Abrahamsson B., and Edgar B. Bioavailability from felodipine extended-release tablets with different dissolution properties. Int. J. Pharm. 60 (1990) 151-156